Quantitation of terameprocol in human plasma by liquid chromatography-tandem mass spectrometry

J Pharm Biomed Anal. 2022 Feb 5:209:114525. doi: 10.1016/j.jpba.2021.114525. Epub 2021 Dec 7.

Abstract

The global transcription inhibitor terameprocol is being evaluated clinically as an oral formulation to treat high-grade glioma. A sensitive, reliable method was developed to quantitate terameprocol using LC-MS/MS to perform detailed pharmacokinetic studies. Sample preparation involved protein precipitation using acetonitrile. Separation of terameprocol and the internal standard, Sorafenib-methyl-d3, was achieved with a Zorbax XDB C18 column (2.1 × 50 mm, 3.5 µm) and gradient elution over a 2-minute total analytical run time. A SCIEX 4500 or SCIEX 5500 triple quadrupole mass spectrometer operated in positive electrospray ionization mode was used for terameprocol detection. The assay range of 5-1000 ng/mL was demonstrated to be accurate (92.7-107.4%) and precise (CV ≤ 11.3%). A sample diluted 1:10 (v/v) was accurately quantitated. Terameprocol in plasma has been proven stable for at least 20 months when stored at -70 °C. The method was applied to the measurement of total plasma concentrations of terameprocol in a patient with a high-grade glioma receiving a 300 mg oral dose.

Keywords: Assay; Tandem mass spectrometry; Terameprocol; Validation.

MeSH terms

  • Chromatography, High Pressure Liquid
  • Chromatography, Liquid
  • Humans
  • Masoprocol / analogs & derivatives
  • Reproducibility of Results
  • Spectrometry, Mass, Electrospray Ionization*
  • Tandem Mass Spectrometry*

Substances

  • terameprocol
  • Masoprocol